Highlights

So, I think the main thing that I would be looking to be coming through by 2025 is effective RSV vaccines, and potentially some small molecule inhibitors. So, I think there may be options for both vaccines and preventative treatment, or treatments, for people who develop RSV, and I would expect that by 2030, the vaccine and drug pipeline will have expanded and being redeveloped, and that the first agents that have maybe achieved licensure will be replaced by other options and/or there may be a broader pallet of options available by 2030.

It [nirsevimab] obviously shows superior efficacy to what’s been reported for palivizumab, and probably more like 70%. The other advantage of the treatment is the modification of the antibody, so it has a more prolonged half-life. I think that agent offers potential opportunities, but I think there are a number of things to consider. The first is, whether that level of efficacy is as good as we can achieve, and it might be that other modifications can further improve on that efficacy. The second is, whether that technology is the most effective technology, and again I think other technologies, I think in a very rapidly expanding area, may come through, and could potentially offer advantages.